• Jorge Perea-Armijo, José López-Aguilera, Rocío Sánchez-Prats, Juan Carlos Castillo-Domínguez, Rafael González-Manzanares, Martín Ruiz-Ortiz, Dolores Mesa-Rubio, Manuel Anguita-Sánchez, and working group of the Heart Failure Unit of Reina Sofia Hospital.
• Heart Failure Unit, Cardiology, Reina Sofia University Hospital, Cordoba, Spain; Institute of Biomedical Research of Cordoba, IMIBIC, Cordoba, Spain.
• Med Clin (Barc). 2023 Jul 7; 161 (1): 1101-10.

BackgroundA percentage of patients with heart failure with reduced ejection fraction (HFrEF) improve left ventricular ejection fraction (LVEF) in the evolution. This entity, defined for the first time in an international consensus as heart failure with improved ejection fraction (HFimpEF), could have a different clinical profile and prognosis than HFrEF. Our main aim was to analyze the differential clinical profile between the two entities, as well as the mid-term prognosis.Material MethodsProspective study of a cohort of patients with HFrEF who had echocardiographic data at baseline and follow-up. A comparative analysis of patients who improved LVEF with those who did not was made. Clinical, echocardiographic and therapeutic variables were analyzed, and the mid-term impact in terms of mortality and hospital readmissions for HF was assessed.ResultsNinety patients were analyzed. Mean age was 66.5(10.4) years, with a male predominance (72.2%). Forty five patients (50%) improved LVEF (Group-1,HFimpEF) and forty five patients (50%) sustained reduced LVEF (Group-2,HFsrEF). The mean time to LVEF improvement in Group-1 was 12.6(5.7) months. Group-1 had a more favorable clinical profile: lower prevalence of cardiovascular risk factors, higher prevalence of de novo HF (75.6% vs. 42.2%; p<0.05), lower prevalence of ischemic etiology (22.2% vs. 42.2%; p<0.05), with less basal dilatation of the left ventricle. At the end of follow-up (mean 19(1) months) Group-1 had a lower hospital readmission rate (3.1% vs. 26.7%; p<0.01), as well as lower mortality (0% vs. 24.4%; p<0.01).ConclusionPatients with HFimpEF seem to have a better mid-term prognosis in terms of reduced mortality and hospital admissions. This improvement could be conditioned by the clinical profile of patients HFimpEF.Copyright © 2023 Elsevier España, S.L.U. All rights reserved.

18 keywords...

hide…